Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Biologics
•
Liver disease
How do you approach the risk/benefit discussion about biologics in patients with cirrhosis?
Related Questions
How would you approach the treatment of inflammatory arthritis (RA) in a patient with multiple sclerosis on natalizumab?
How do you counsel patients who prefer to continue TNFi therapy indefinitely for rheumatoid arthritis despite long-standing remission?
How would you approach rheumatoid arthritis treatment for widespread large rheumatoid nodules but no active synovitis or subjective joint pain?
How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
Do you consider new onset autoimmune disease (e.g. seronegative rheumatoid arthritis) a few months after completing immunotherapy for cancer to be an immune-related adverse effect to the immunotherapy?
Would you consider utilizing a TNF-inhibitor in a patient with RA/SLE overlap who has already tried methotrexate, hydroxychloroquine, and abatacept?
Do you offer LDRT for psoriatic arthritis, rheumatoid arthritis, or polymyalgia rheumatica or fibromyalgia?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
What is your approach for managing DMARDs in patients with rheumatoid arthritis and newly diagnosed HIV?
